Breast Neoplasms, Male

2

Review clinical trials related to Breast Neoplasms, Male. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for HR+/HER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.

Participants needed: 3,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoUpdated: Feb 3, 2025Locations: 24
Eligibility criteria

Diagnosis of HR+/HER2- advanced Breast Cancer (aBC), as defined as at least 1% e... [+1]

Less than 3 months of follow up from the CDK4/6i start to the date of data cut-o... [+2]

Status: Recruiting

MALE Mamm Organoids

It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor. Furthermore, the development of such preclinical models could be of significant support for the identification of specific personalized and ad hoc therapeutic treatments for male pathology.

Participants needed: 7
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: Regina Elena Cancer InstituteUpdated: Jan 22, 2025Locations: 1Duration: 36 Months
Eligibility criteria

Men aged >18 years [+3]